PHASE II CLINICAL TRIALS OF NEW CHEMOPREVENTIVE AGENTS NIH GUIDE, Volume 23, Number 7, February 18, 1994 RFP AVAILABLE: NCI-CN-45593-32 P.T. Keywords: National Cancer Institute The National Cancer Institute (NCI) is seeking contractors qualified to perform Phase II Clinical Trials that are small short-term, efficient studies of potential chemopreventive agents. This work includes small, short-term, efficient studies to determine the dose of a given chemopreventive agent that exhibits a pharmacodynamic effect on an intermediate endpoint. These studies will also require dose response studies to determine the minimum dose at which a biological effect is observed and confirmation of the maximum safe dose, and the performance of randomized blinded trials in small groups of subjects whose endpoints will be the measurable biological effect of the agent versus a placebo. This solicitation is an annual announcement to expand a current pool of Master Agreement (MA) Holders qualified to perform this type of work. Individual work requirements will be defined, as the need arises, by Master Agreement Orders issued during the period of performance, and Master Agreement Orders will be awarded based on competition between members of the MA pool. The solicitation will be released on or about February 22, 1994, with proposals due April 22, 1994. INQUIRIES The Contracting Officer for this solicitation is Richard L. Hartmann on telephone (301) 496-8603. Copies of the RFP may be obtained by sending a written request to: Ms. Desiree Sylver-Foust Research Contracts Branch National Cancer Institute Executive Plaza South, Room 635 Bethesda, MD 20892 Telephone: (301) 496-8603 .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, RealPlayer, Video or Flash files, see Help Downloading Files. |